Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2024 08:00 ET | Source: CG Oncology Inc.

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 03, 2024 11:23 ET | Source: CG Oncology Inc.

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 26, 2024 08:00 ET | Source: CG Oncology Inc.

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 24, 2024 10:00 ET | Source: CG Oncology Inc.

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
March 28, 2024 08:00 ET | Source: CG Oncology Inc.

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...
February 27, 2024 08:00 ET | Source: CG Oncology Inc.

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

- PIVOT-006 Phase 3 open-label trial of adjuvant cretostimogene is CG Oncology’s earliest disease stage clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) - - Primary...